| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAMTS12 |
| Uniprot No | P58397-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-229aa |
| 氨基酸序列 | MPCAQRSWLANLSVVAQLLNFGALCYGRQPQPGPVRFPDRRQEHFIKGLP EYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEK DLFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGT RVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKV PETKEPTCGLKGIVTHMSSWVEESVLFFW |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAMTS12重组蛋白的3篇代表性文献(名称、作者及摘要内容概括)：
---
1. **文献名称**: "ADAMTS12: A multifaced metalloproteinase in cancer and tissue remodeling"
**作者**: Rodríguez-Baena FJ, et al.
**摘要**: 该研究探讨了重组ADAMTS12蛋白在肿瘤微环境中的作用，发现其通过切割细胞外基质蛋白(如纤连蛋白)抑制肿瘤侵袭和转移，并揭示了其蛋白酶活性对血管生成的调控机制。
---
2. **文献名称**: "Recombinant expression and functional characterization of ADAMTS12 in osteoarthritis pathogenesis"
**作者**: Liu Y, et al.
**摘要**: 研究利用哺乳动物细胞系统成功表达重组ADAMTS12蛋白，发现其通过降解软骨聚集蛋白聚糖(aggrecan)参与骨关节炎进程，并验证了其抑制剂在体外模型中的保护作用。
---
3. **文献名称**: "ADAMTS12 modulates inflammation through interaction with TNF-α signaling pathways"
**作者**: García-Castro A, et al.
**摘要**: 通过重组ADAMTS12蛋白的功能实验，证明其能与TNF-α受体结合并抑制NF-κB信号通路，提示其在炎症性疾病(如类风湿性关节炎)中的潜在治疗价值。
---
如需更多文献或具体研究方向的扩展，可进一步说明需求。
ADAMTS12 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 12) is a member of the ADAMTS family of extracellular matrix (ECM)-associated proteases, known for their roles in remodeling the ECM, regulating cell-matrix interactions, and influencing cellular signaling pathways. This multidomain enzyme contains conserved structural features, including a propeptide, metalloprotease domain, disintegrin-like segment, thrombospondin type 1 repeats (TSRs), and a cysteine-rich region. ADAMTS12 is synthesized as an inactive zymogen and undergoes proteolytic activation to exert its enzymatic activity, primarily targeting proteoglycans and other ECM components.
The recombinant ADAMTS12 protein is engineered through molecular cloning techniques, typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications and folding. Its production enables detailed biochemical and functional studies, overcoming challenges associated with low endogenous expression levels in tissues. Recombinant ADAMTS12 has been instrumental in elucidating its substrate specificity, interaction partners, and regulatory mechanisms. Research highlights its involvement in developmental processes, tissue homeostasis, and disease pathologies such as cancer, osteoarthritis, and fibrosis. For instance, ADAMTS12 exhibits dual roles in tumorigenesis—acting as both a tumor suppressor by inhibiting angiogenesis and a promoter by facilitating cancer cell invasion through ECM degradation.
In therapeutic contexts, recombinant ADAMTS12 holds potential for applications in regenerative medicine and targeted therapies. Its ability to modulate ECM dynamics makes it a candidate for treating fibrotic disorders or cartilage degeneration. However, challenges remain in understanding its context-dependent functions and optimizing delivery strategies. Ongoing studies aim to unravel its complex biology and harness its recombinant form for diagnostic or interventional tools, bridging gaps between basic research and clinical translation.
×
